482
Participants
Start Date
September 14, 2020
Primary Completion Date
January 16, 2023
Study Completion Date
January 16, 2023
Dihydroergotamine
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Montefiore Medical Center, The Bronx
SPRI Clinical Research, Brooklyn
Thomas Jefferson University/Jefferson Headache Center, Philadelphia
Georgetown University Hospital, Department of Neurology, McLean
Charlottesville Medical Research, Charlottesville
PharmQuest, Greensboro
PMG Research of Wilmington, Wilmington
Multi-Specialty Research Associates, Lake City
Complete Health Research, Ormond Beach
Hillcrest Medical Research, DeLand
ClinCloud, Maitland
CNS Health Care - Orlando, Orlando
MD Clinical, Hallandale
Behavioral Clinical Research, Miami Lakes
Biotech Pharmaceuticals, Miami
Infinity Clinical Research, Sunrise
Palm Beach Research Center, West Palm Beach
Santos Research Center, Corp, Tampa
Clinical Research CF, Winter Haven
CNS Healthcare - Memphis, Memphis
Rapid Medical Research, Cleveland
CTI Clinical Research Center, Cincinnati
Neurology Diagnosis, Dayton
Integrated Clinical Trial Services, Inc, West Des Moines
Montana Medical Research, Missoula
Healthcare Research Network, Hazelwood
Clinvest Research, Springfield
Delricht Research, Prairieville
Delricht Research, Tulsa
DM Clinical Research, Tomball
FutureSearch Trials of Neurology, Austin
Advanced Clinical Research, Meridian
Albuquerque Clinical Trials, Albuquerque
Wake Research - Clinical Research Center of Nevada, Las Vegas
Downtown LA Research, Los Angeles
Clinical Research Institute, Los Angeles
WR-PRI, Los Alamitos
Collaborative Neuroscience, Long Beach
WR-PRI, Encino
WR-PRI, Newport Beach
Medvadis Research at Boston PainCare Center, Waltham
Dartmouth-Hitchcock Neurology Headache Clinic, Lebanon
Hassman Research Institute, Berlin
Omega Medical Research, Warwick
Satsuma Pharmaceuticals, Inc.
INDUSTRY